Navigation Links
ARUP Labs signs agreement with UH Case Medical Center to distribute novel DEEPGEN HIV test
Date:7/17/2014

CLEVELAND University Hospitals (UH) Case Medical Center has signed an agreement with ARUP Laboratories, a major national clinical reference laboratory that offers an extensive menu of highly complex and unique medical tests to hospitals, medical schools, and other nonprofit and commercial organizations throughout the United States.

Under the agreement, ARUP will include in its menu of tests an HIV diagnostic test invented at University Hospitals' Translational Laboratory by Miguel Quinones-Mateu, PhD, scientific director at the UH lab and assistant professor at the Department of Pathology, Case Western Reserve University School of Medicine.

The novel test, DEEPGENHIV, monitors the success of anti-HIV treatment by determining drug resistance and the ability of the virus to infect different cells based on deep genetic sequencing. ARUP, a nonprofit enterprise of the University of Utah, will include DEEPGEN in its menu of tests and will nationally market the assay. Clinical samples will then be referred to UH Translational Laboratory in Cleveland from all 50 states.

DEEPGENHIV provides a sensitive platform for HIV physicians and researchers, both in the academia and industry. The assay allows the detection of minority variants at frequencies unimaginable with current HIV genotypic tests based on standard (Sanger) sequencing.

"Although the clinical relevance of these minority members of the viral population is still under debate, it is reasonable to assume that the earlier these mutant viruses are detected, the sooner the proper strategy can be defined to control their growth," said Dr. Quiones-Mateu. "DEEPGENHIV is now the primary HIV genotyping assay used by HIV physicians at the Case Western Reserve University/University Hospitals AIDS Clinical Trials Unit, and we have been analyzing clinical specimens from other institutions around the region. This agreement with ARUP will expedite the use of this innovative and highly sensitive assay nationwide, which will allow us to enhance the care and treatment of HIV-infected individuals across the country."

"I am excited about our relationship with ARUP, as it appears to be a natural synergy that we both may leverage to expand the quality of diagnostic testing and care provided to patients with HIV nationally," said Ronald E. Dziedzicki, chief operating officer at UH Case Medical Center.

"Our relationship with UH Case Medical Center enables ARUP to offer this innovative test to our clients for the management of patients with HIV," said Jerry Hossong, MD, DDS, ARUP's chief medical officer and director of laboratories. "We are very pleased to include this test as part of our comprehensive menu of services."


'/>"/>

Contact: George Stamatis
george.stamatis@uhhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert  

Related biology news :

1. Small non-coding RNAs could be warning signs of cancer
2. Quick test finds signs of diarrheal disease
3. A*STAR signs agreement with Nestlé to strengthen food & nutrition R&D in Singapore
4. Research reveals new understanding, warning signs, and potential treatments for multiple sclerosis
5. Switzerland signs the ELIXIR consortium agreement and contributes €35 million
6. BioClaim, Inc. Signs Biometric Software Contract with Amerigroup Florida
7. Leopoldina signs cooperation agreement with the Academy of Science of South Africa
8. Fluke Biomedical launches portable, feature-rich ProSim 3 and 2 Vital Signs Simulators
9. Light and nanoprobes detect early signs of infection
10. Encouraging signs for bee biodiversity
11. Early warning signs of population collapse
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
ARUP Labs signs agreement with UH Case Medical Center to distribute novel DEEPGEN HIV test
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... NEWARK, Del. , March 29, 2017 ... medicine company, and W. L. Gore & ... announced a collaborative research agreement whereby the two companies ... delivery device technologies that provide protection from immune rejection. ... has been developing innovative stem cell-derived cell replacement therapies ...
(Date:3/29/2017)... 29, 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" or ... a new risk stratification test for breast cancer, via its ... Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker test with a ... for developing breast cancer.   ... BreastSentry measures the fasting plasma levels ...
(Date:3/29/2017)... 2017 The Global Microfluidic Chips Market by ... specialized and comprehensive study on the existing state of the global ... Europe and Asia-Pacific , ... and Africa . ... Browse 172 Tables and Figures, 13 Major ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... NetDimensions Learning to replace paper-based processes and enhance training plan management for consistent ... very pleased to partner with the SHL Group to help improve and streamline ...
Breaking Biology Technology: